# Amylyx Pharmaceuticals, Inc. (AMLX)

> Source: Nexqual · https://nexqual.com/AMLX · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Amylyx Pharmaceuticals, Inc. (AMLX), nexqual.com/AMLX" · informational, not investment advice.

**Price:** USD 27.65 (+2.29% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 27.03 · day 27.45–28.34 · 52w 10.83–41.14 · market cap $3.47B · NMS

## Key facts
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 42.36 (range 20–57).
- Total return with dividends: 1Y +82.3% vs S&P 500 +18.1%; 5Y +53.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.37, revenue estimate $38K.

## Analysts
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 42.36 (low 20, high 57).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | Citigroup | Target raised | Buy | $32 → $39 |
| 2026-08-27 | Guggenheim | Target raised | Buy | $55 → $57 |
| 2026-08-19 | Mizuho | Target raised | Outperform | $30 → $42 |
| 2026-08-19 | Guggenheim | Target raised | Buy | $40 → $55 |
| 2026-08-19 | Baird | Target raised | Outperform | $28 → $52 |
| 2026-08-18 | HC Wainwright & Co. | Target raised | Buy | $34 → $55 |
| 2026-08-17 | Mizuho | Target raised | Outperform | $24 → $30 |
| 2026-08-03 | Citigroup | Target raised | Buy | $20 → $26 |
| 2026-07-20 | Mizuho | Target raised | Outperform | $21 → $24 |
| 2026-06-25 | Guggenheim | Target raised | Buy | $30 → $40 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2022-01-03) |
|---|---|---|
| Total return | +82.3% | +53.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +82.6% | +9.3% |
| Volatility (annualized) | 75.8% | 116.5% |
| Max drawdown | -32.3% (Aug 2026→Oct 2026) | -96.0% (Jan 2023→Jun 2024) |

## Peers (Drug Manufacturers - Specialty & Generic)
LQDA (Liquidia Corporation) USD 34.78 +29.73% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · KNSA (Kiniksa Pharmaceuticals Interna) USD 79.94 +1.80%

## More
Full page: https://nexqual.com/AMLX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt